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Abstract 
Purpose: To analyze the rationality of antimicrobial usage and factors influencing it over the period of 
January to December 2010 in Fatmawati General Hospital, Jakarta, Indonesia. 
Methods: Present study was conducted in the intensive care unit of Fatmawati General Hospital, 
Jakarta, Indonesia. Gyssens method was used to assess the rationality of antimicrobial use. Data for 
this retrospective, cross-sectional study were drawn from patients’ medical record files. Multivariate 
analysis with ordinal logistic regression was used to determine the dominant factors affecting the 
appropriateness of antimicrobial use. 
Results: Data for 410 patients from the intensive care unit (ICU) was collected. There were 912 
antimicrobial regimens prescribed for these patients. Based on Gyssens method, 805 antimicrobial 
regimens were empirical and 107 definitive. Of the empirical regimens, 596 (74.03 %) were 
inappropriate, while of the definitive regimens, 84 (78.51 %) were inappropriate. Site of infection, 
comorbid conditions and economic status of patients were the main factors that influenced the 
appropriateness of antimicrobial treatment choice. 
Conclusion: A higher degree of irrational use of antimicrobial agents occurs in the ICU of the hospital 
studied, this can lead to increase in the burden of disease. 
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Antibiotics use is common in hospitalized 
patients especially in surgical procedures and 
Intensive Care Unit (ICU) as a therapy for 
infection or prophylactic measures [1-3]. 
Increasing antimicrobial resistance due to 
irrational use of antimicrobial agents is a serious 
issue worldwide [4]. Different studies have 
reported the inappropriate use of antimicrobial 
agent in developing countries [5]. Hadi et al 
reported that 44 to 97 % of patients in an 
Indonesian hospital were prescribed with 
unnecessarily antibiotics regimen [6].  
 
Gyssens et al developed a new protocol for 
appropriate use of antimicrobial while working in 
University Hospital Nijmegen, Netherland in 
1996. They studied the impact of interventions 
and compared the results with study carried 
before improved guidelines. A decrease in 
antibiotic use before and after regimen was 
noticed. Gyssens et al determined categories of 
rational antimicrobial prescription regarding 
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appropriateness, pharmacodynamic and 
socioeconomic status of patient [7]. Several 
studies were carried out to evaluate 
appropriateness of antibacterial usage on the 
basis of Gyssens protocol.  
 
In 2010, Parisot et al evaluated the quality of 
antibiotic usage in intensive care units of two 
Hospitals in France and results revealed that 
among 113 patients, 7 % were prescribed with 
too broad spectrum antimicrobial agents, 8 % 
unjustified associated, 20 % wrong posology, 1 
%  incorrect route of administration, 6 % wrong 
interval and 7 % were lacking  plasmatic dosage 
[8]. Apisarnthanarak et al found a decrease trend 
of irrational use of antimicrobial agents from 91-
25 % before and after antibiotic control program 
in a teaching hospital of Thailand [9]. Usman 
Hadi and colleagues conducted a study to 
investigate the appropriate use of antibiotics in 
two teaching hospital of Java, Indonesia using 
the Gyssens method. They found that 84 % 
patients were prescribed with antibiotics and 
60% of them were inappropriate and 34 % 
antibiotic prescriptions in Hospital A and 48 % in 
Hospital B were without indications [6]. 
 
Previous studies conducted in Fatmawati 
General Hospital (FGH), Indonesia focused on 
the intensity, quantity and sensitivity of antibiotics 
usage [10]. FGH has never developed any 
guidelines for clinicians regarding the use of 
antibiotics and that can result in irrational choices 
of antibiotics. No studies have also been carried 
out to investigate the appropriateness of 
antimicrobial usage in FGH using Gyssens 
method. The aim of this study, therefore, was to 
assess the appropriateness of antimicrobial 




This is a retrospective, cross-sectional study 
conducted in Intensive Care Unit (ICU) of 
Fatmawati General Hospital (FGH). The data 
were drawn from registration forms, daily 
instruction forms and medical records of those 
patients who were treated with antimicrobial 
regimens and hospitalized for at least 48 h in ICU 
of FGH, during January-December 2010. 
Gyssens protocol was applied to determine 
appropriateness of antimicrobial agents 
prescribed in FGH. Gyssens et al divided 
antimicrobial usage in six main categories, 
appropriate (category 0), inappropriate timing 
(category I), inappropriate dose and route of 
administration (category IIa, IIb, IIc), 
inappropriate duration (category IIIa, IIIb), 
inappropriate type (IVa, IVb, IVc, IVd), 
inappropriate indication (category V), and 
incomplete data (category VI) [5]. 
 
Statistical analysis  
 
Descriptive analysis of data was carried out on 
the basis of characteristics of the research 
subjects by using bivariate and multivariate 
analyses. SPSS version 17 software was used to 
analyze the data while keeping the degree of 
confidence as 95 % with a p-value of 0.05. 
Findings of this study were compared with 
available literature to determine appropriateness 
of antimicrobial usage in the ICU of FGH. The 
Sanford Guide to Antimicrobial Therapy (2010), 
Drug Information Handbook (2010); Applied 
Therapeutics: The Clinical Use of Drugs (2009), 
Pharmacotherapy: A Pathophysiologic Approach 
(2008) and Principles and Practice of Infectious 
Disease (2005), were used to assess the 




There were 819 patients treated in the ICU of 
FGH from January to December 2010 and 410 of 
them met the inclusion criteria of this study. 
Among these 410 patients, 200 (48.78 %) 
patients belonged to poor families while 118 
(28.78 %) patients have health insurance. There 
were 31 types of antimicrobial agents used in 
912 regimens prescribed to these patients. 
Antimicrobial agents in 805 (88.27 %) 
prescriptions were used as empirical therapy and 
in 107 (11.73 %) prescription was definitive 
therapy. There were 156 (38 %) Patients who 
underwent surgical procedures such as 
laparotomy, appendectomy and craniotomy were 
treated with antimicrobials as an empirical 
therapy. Information regarding antimicrobial 
agents used in ICU of FGH is mentioned in Table 
1. 
 
The most commonly used empirical antimicrobial 
was ceftriaxone, used in 281 regimen (34.91 %). 
The second most frequently prescribed empirical 
antibacterial was metronidazole with 84 (10.43 
%) regimens whereas levofloxacin and 
meropenem were used in 66 and 48 empirical 
regimens. Cefoperazone, ciprofloxacin and 
ceftazidime were also common empirical 
antimicrobials in our cohort. The top 3 
antimicrobials used as definitive therapy were 
phosphomycin, meropenem and ciprofloxacin, 
used in 25 (23.36 %), 18 (16.82 %) and 10 (9.35 
%) regimens respectively. 
 
 
Luciana et al 
Trop J Pharm Res, April 2015; 14(4):   
 
709 
Table 1: Antimicrobial profile of patients in the ICU of Fatmawati General Hospital, Jakarta, Indonesia 
 
Antimicrobial  Empirical (%) Definitive  (%) 
Amikacin 13 1.61 8 7.48 
Ampicillin-sulbactam  28 3.48 9 8.41 
Azithromycin  1 0.12 0 0.00 
Ethambutol 15 1.86 0 0.00 
Fluconazole 12 1.49 0 0.00 
Phosphomycin 19 2.36 25 23.36 
Gentamicin  7 0.87 2 1.87 
Imipenem–cilastatin 12 1.49 4 3.74 
Isoniazide 14 1.74 0 0.00 
Kanamycin 1 0.12 0 0.00 
Clarithromycin 1 0.12 0 0.00 
Levofloxacin 66 8.20 8 7.48 
Meropenem 48 5.96 18 16.82 
Metronidazole 84 10.43 0 0.00 
Micafungin 1 0.12 0 0.00 
Ofloxacin  2 0.25 1 0.93 
Pyrazinamide 10 1.24 0 0.00 
Rifampicin  16 1.99 0 0.00 
Cefepime 9 1.12 3 2.80 
Cefixime 0 0.00 2 1.87 
Cefoperazone 44 5.47 3 2.80 
Cefoperazone-sulbactam  23 2.86 0 0.00 
Cefotaxime 5 0.62 0 0.00 
Cefotiam 1 0.12 0 0.00 
Cefpirome 4 0.50 1 0.93 
Ceftazidime 31 3.85 9 8.41 
Ceftizoxime 9 1.12 0 0.00 
Ceftriaxone 281 34.91 1 0.93 
Ciprofloxacin 41 5.09 10 9.35 
Streptomycin 6 0.75 0 0.00 
Vancomycin 1 0.12 3 2.80 
 Total 805 100.00 107 100.00 
 
Correlation of rationality or appropriateness  
 
In the treatment of infection related main 
illnesses, 468 (51.32 %) empirical antimicrobial 
regimen were used. Ceftriaxone was used in 217 
(46.37 %) of these regiments. According to 
Gyssens categories, Inappropriate use of 
ceftriaxone (category I-V) for treating infection-
related main illnesses was seen in a total of 189 
(49.35 %) regimens, and only 28 (32.94 %) 
regimens were found to be appropriate (category 
0). In 143 (62.72 %) regimens, ceftriaxone was 
found inappropriate regarding the spectrum of 
antimicrobial activity (category IV).The 
inappropriate duration of ceftriaxone use was 
found in 18 (29.51 %) regimens employed to 
treat infection related main illness. 
 
Metronidazole was the second most frequently 
used antibiotic as it was employed in 77 (16.45 
%) regimens. There were 151 (36.83 %) 
antibiotic regimens that contain metronidazole. It 
was found that 26 (42.62 %) regimens containing 
metronidazole were inappropriate either 
regarding the duration of therapy (category III) or 
inappropriate concomitant agents. The use of 
metronidazole in combination with meropenem, 
cefoperazone or sulbactam for the therapy of 
post operative intraabdominal infections without 
indication (category V) was seen in 17 (30.36 %) 
regimens.  
 
Meropenem was found in 26 (5.56 %) 
prescriptions indicated for infection related main 
illnesses like sepsis and intraabdominal surgery. 
The choice of meropenem was found 
inappropriate in 12 (5.26 %) regimens (category 
IV) whereas inappropriate use of meropenem 
(category I-V) in patients was seen in 26 (6.79 
%) regimens. The correlation between rationality 
of empiric antimicrobial use and the presence of 
infection-related main illnesses was tested by 
Chi-square and it is given in Table 2. It was 
found that appropriateness of empirical 
antimicrobial treatment was significantly 
influenced by the presence of infection related 
main disease (p < 0.001). 
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Table 2: Correlation between rationality/appropriateness of empiric antimicrobial use with the presence of infection-
related main illnesses, based on Gyssens method 
  
 Variable Gyssens category Total P-value 0 1 2 3 4 5 
Infection-related 




85 9 29 61 228 56 468   
Total 209 17 69 108 323 79 805   
 
Table 3: Correlation between rationality/appropriateness of empiric antimicrobial use and the presence of infection-





0 1 2 3 4 5 
Presence of infection-related 
accompanying illness 124 8 40 47 94 23 336 <0.001 
Absence of infection-related 
accompanying illness 85 9 29 61 229 56 469   
Total 209 17 69 108 323 79 805   
 
Correlation between rationality of empiric 
antimicrobial therapy and infection-related 
illnesses  
 
The common infection related accompanying 
illnesses in the ICU of FGH were pneumonia, 
pleural effusion, and fungal infections. Data of 
191 (46.59 %) patients with infection related 
concomitant illnesses was assessed on Gyssens 
protocol. The most common antimicrobial agent 
used as the empiric therapy to treat infection-
related accompanying illness was ceftriaxone, 
used in 63 (18.75 %) regimens. The choice of 
ceftriaxone to treat these morbidities was found 
to be the inappropriate choice (category IV) in 33 
(35.11 %) regimens and inappropriate duration of 
administration (category III) in 10 (21.28 %) 
regimens. Inappropriate use of ceftriaxone in 
treating infection-related accompanying illnesses 
was found in 50 (23.58 %) regimens. In contrast, 
the appropriate use of ceftriaxone (category 0) 
was seen in 13 (10.48 %) regimens.  
Levofloxacine was second most common 
antimicrobial agent used as an empiric therapy to 
treat infection related accompanying illness as it 
was found in 58 (17.26 %) regimens. Use of 
levofloxacine without indication (category V) was 
seen in 4 (17.39 %) regimens. Inappropriate use 
of levofloxacine (category I-V) for managing 
aforementioned accompanying illnesses was 
seen in 34 (16.04 %) regimens. In contrast, the 
appropriate use was found in 24 (19.35 %) 
regimens. 
 
The third most widely used antimicrobial empiric 
therapy in infection-related accompanying 
illnesses was ciprofloxacine, given in 29 (8.63 %) 
regimens. Inappropriate use of ciprofloxacine, 
related to duration of therapy (Category III) was 
found in 8 (17.02 %) regimens whereas irrational 
use of ciprofloxacine in all categories (category I-
V) was found in a total of 21 (6.25 %) regimens. 
The correlation between the rational empiric 
antimicrobial therapy and infection related to 
accompanying illnesses was found significant (p 
< 0.001), as shown in Table 3. 
 
Correlation between the rationality of empiric 
antimicrobial agents and doctor’s approach  
 
Patients treated in the ICU of FGH remain under 
the observation of more than one doctor. Patient 
remained under treatment of some specialists 
before admitted to the ICU. Clinicians who were 
involved in the prescription of antimicrobial 
agents for patients treated in the ICU include 
anesthesiologists (intensive care consultants), 
surgeons (neurosurgeons, thoracic surgeons, 
digestive surgeons, general surgeons, and 
oncologic surgeons) 310 (38.51 %) were from 
empiric therapy, while 14 pulmonologists were 
from definitive group of therapy. Further details 
are shown in Table 4. 
 
Frequency of prescribed empiric antimicrobial 
agents in the ICU of our hospital by surgeons 
was recorded in 310 (38.51 %) regimens. 
Ceftriaxone was observed in 161 (51.94 %) 
regimens, approximately half of the total 
antimicrobial prescriptions made by surgeons. 
Inappropriate prescription of ceftriaxone 
(category I-V) made by surgeons was seen in 
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Type of antimicrobial therapy Total Empiric (%) Definitive (%) 
Intensive Care 
Consultants 142 17,64 64 59.81 206 
Surgeons 310 38,51 15 14.02 325 
Pulmonologists 161 20,00 14 13.08 175 
Internists 96 11,93 13 12.15 109 
Obstetricians and 
gynecologists 34 4,22 1 0.93 35 
Neurologists 42 5,22 0 0.00 42 
Orthopedic 
surgeons 20 2,48 0 0.00 20 
Total 805 100 107 100.00 912 
 
146 (55.09 %) regimens. There were 15 (33.33 
%) ceftriaxone prescriptions by surgeons that 
were appropriate according to Gyssens method 
(category 0). Metronidazole was the second most 
commonly implied empiric antibiotic by the 
clinicians. Inappropriateness in metronidazole 
containing regimens prescribed by surgeons was 
related to the duration of therapy (category III) in 
17 (44.74 %) regimens and without indication 
(category V) in 14 (40 %) regimens. There were 
25 (55.56 %) appropriate (category 0) and 35 
(13.21 %) (category I-V) inappropriate 
metronidazole regimen implied by surgeons. 
 
The second most common doctors who 
prescribed empiric antimicrobial agents in the 
ICU were the intensivists, in 142 (17.64 %) 
regimens. The most frequent empiric 
antimicrobial agent prescribed by intensivists 
was ciprofloxacine, in 24 (16.9 %) regimens. 
Irrational approach related to the duration of 
therapy (category III) was seen in 6 (20.69 %) 
regimens. There were 6 (14.29 %) appropriate 
regimens (category 0) and 18 (18 %) 
inappropriate regimens (category I-V) of 
ciprofloxacine by intensivists. Ampicillin-
sulbactam combination was observed as the 
second most frequent antimicrobial agent implied 
in 20 (14.08 %) regimens by intensivists. 
Empirical therapy of ampicillin-sulbactam in 9 
(26.47 %) regimens by intensivists was 
inappropriate choice (category IV). Ampicillin-
sulbactam was used as an empiric therapy in 
patients with CAP and sepsis.  
 
The third most common doctors who prescribed 
empiric antibiotics were pulmonologists, in 155 
(19.25 %) regimens. They most commonly 
prescribed levofloxacine as empiric therapy in 35 
(22.58 %) regimens. Inappropriate duration of 
treatment with levofloxacine was found in 9 
(47.37 %) regimens.  
 
The second most frequently prescribed empiric 
antimicrobial agent by pulmonologists was 
ceftriaxone, in 27 (17.42 %) regimens. 
Inappropriate prescription of ceftriaxone by 
pulmonologists as an inappropriate choice 
(category IV) was found in 11 (50 %) regimens. 
There were 6 (8.11 %) appropriate prescription 
(category 0) and 21 (25.93 %) inappropriate 
prescriptions (category I-V) of ceftriaxone by 
pulmonologists. 
 
The internists prescribed antimicrobial agents in 
98 (12.17 %) regimens. The most frequently 
prescribed antimicrobial was again ceftriaxone, in 
36 (36.73 %) regimens. Ceftriaxone was chosen 
by internists as an empiric therapy for chronic 
pulmonary disease in 21 (45.65 %) regimens. 
There were 6 (33.33 %) appropriate regimens 
(category 0) and 30 (37.5 %) inappropriate 
regimens of ceftriaxone by internists. 
 
Neurologists prescribed 42 (5.22 %) antimicrobial 
regimens. They most frequently prescribed 
ceftriaxone, in 24 (57.14 %) regimens. It was 
inappropriate type of empiric therapy for 
infectious diseases (category IV) in 14 (58.33 %) 
regimens. The prescriptions of ceftriaxone by 
neurologists was found to be appropriate 
(category 0) in 6 (60 %) regimens and 





The most commonly used empirical antimicrobial 
agent in our cohort was ceftriaxone (34.91 %). 
The choice of ceftriaxone was based upon the 
knowledge of the prescriber and the economic 
status of the patient. Phosphomycin was most 
frequently prescribed antibacterial drug with 25 
(23.36 %) definitive therapy regimens. Choice of 
Phosphomycin was based upon bacterial culture 
sensitivity test of sputum and pus of patients. 
Bacteria such as P. aeruginosa, A. Baumanii and 
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Klebsiella sp were isolated from these cultures. 
These micro organisms often develop multi-drug 
resistant and found in patients with severe 
infections and contribute to high mortality rate 
[16]. Phosphomycin related bacterial resistance 
frequently observed by the researchers [16]. 
 
Ceftriaxone was used in 217 (46.37 %) regimens 
employed to treat infection related main illness. 
Ceftriaxone was main drug prescribed in 
abdominal and cranial surgeries. In 143 (62.72 
%) regimens, ceftriaxone was found 
inappropriate (category IV). Ceftriaxone was 
used as single agent in post laparotomy patients. 
Intraabdominal infections can be caused by 
either gram negative or gram positive bacteria, 
more likely by anaerobic bacterias. 
Cephalosphorins do not possess antimicrobial 
activity against anaerobic bacteria that can result 
in failure of therapy. Conversely, they should be 
used together with an anti-anaerobic agent. 
Inappropriate antibiotic choice in treating 
intraabdominal infection can cause poor patient 
outcome [17]. 
 
Ceftriaxone was the most common antimicrobial 
agent used as empiric therapy to treat infection-
related accompanying diseases (63 regimens). 
Ceftriaxone was often used in treating infection-
related comorbidities such as community-
acquired pneumonia (CAP) and sepsis. 
Ceftriaxone used in treating CAP and sepsis was 
often as a monotherapy. In many cases, the 
patients were in septic shock because of the 
inappropriate use of ceftriaxone. Antimicrobial 
agents used to treat sepsis was based on the 
location of the infection. The ideal antibiotic used 
for treating sepsis should have low resistance, 
minimal side effects, and a good strength in 
combating pathogenic bacteria based on the 
location of the infection [18]. Patients with severe 
sepsis or septic shock warrant broad spectrum 
therapy until the causative pathogen and its 
antibiotic susceptibilities are defined. Restriction 
of antibiotics as a strategy to reduce the 
development of antimicrobial resistance or to 
reduce cost is not an appropriate initial strategy 
in these patients [12]. 
 
In our cohort, levofloxacine was used for 
inappropriate duration (category III) in 15 (31.91 
%) regimens. The administration of 750 mg of 
levofloxacine to treat patients with 
bronchopneumonia was for 6 - 17 days. 
Prolonged use of levofloxacine in the treatment 
of pneumonia might be due to the absence of 
evaluation of therapy on transfer of the patients 
to general ward where antibiotic was continued. 
Dunbar et al found that 750 mg of levofloxacine 
per day for 5 days was at least as effective as 
500 mg per day for 10 days to treat mild-to-
severe CAP. Moreover, high-dose and short-
course of levofloxacin regimen maximizes 
concentration dependent antibacterial activity, 
decreases the potential of drug resistance and 
show better patient compliance [19,20]. 
 
Ciprofloxacin was the third most widely used 
antimicrobial empiric therapy in infection-related 
accompanying illnesses (29 regimens). Use of 
ciprofloxacine in the ICU of FGH was mainly 
intended to treat CAP and nosocomial 
pneumonia. Inappropriate duration of 
ciprofloxacin was found in 8 regimens. The 
administration of ciprofloxacine as a therapy for 
CAP and sepsis was continued for 14 - 25 days. 
Clinical evaluation revealed that ciprofloxacine 
was failed to improve patient condition.  
Successful antibiotic therapy is assessed by a 
febrile phase for 48-72 h following minimum of 5 
days antimicrobial treatment [21].  Mild to 
moderate gastrointestinal tract adverse events 
were observed with ciprofloxacin. Reported 
adverse effects of ciprofloxacine are 
photosensitivity, diarrhea, vomiting and nausea, 
liver function abnormalities, insomnia, headache 
and rash [22]. 
  
Ceftriaxone was found to be an inappropriate 
antimicrobial therapy (category IV) in 110 (64.71 
%) regimens made by surgeons. Inappropriate 
choice of antimicrobial agent was mostly found in 
patients who underwent abdominal surgeries. 
Bacteroides fragilis was the most prominent 
pathogen causing intraabdominal infections. 
Cephalosphorins were often used to treat 
intraabdominal infections, but they do not exhibit 
anti-anaerobic properties and must be used in 
conjunction with an anti-anaerobic agent. 
Bacteroides fragilis showed sensitivity towards 
metronidazole, carbapenem, and inhibitors of 
beta lactam-beta lactamase activity. This was the 
reason why the use of cephalosphorins to treat 
intraabdominal infections were often combined 
with metronidazole [17,23].  
 
Pulmonologists prescribed levofloxacin as 
empiric antimicrobial therapy 35 regimens. It was 
prescribed to treat CAP and HAP in the ICU of 
FGH. Inappropriate duration of therapy with 
levofloxacine was seen in 9 regimens.  
Levofloxacine (750 mg) was used for 6-13 days, 
while 500 mg of levofloxacine was used for 22 
days. Patients with CAP were given a 
combination of ceftriaxone and 750 mg dose of 
levofloxacine. After patients showed clinical 
improvements, they were moved to the general 
ward and the antibiotics were continued even 
though their supporting data (white cell count, 
temperature and chest x-ray) showed 
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improvements. Patients suffering from CAP were 
also given a combination of ceftriaxone and 500 
mg dose of levofloxacine. This combination was 
used for 22 days as the patients were transferred 
to the general ward and it was continued 
because the chest X-ray of the patients showed 
pleural effusion. Levofloxacin is a concentration-
dependent antimicrobial agent, a high-dose (750 
mg), short-course (5-day) was based on the 
rationale that higher concentration peaks lead to 
increased killing of the pathogen, decreased 
resistance development and higher patient 
compliance with the shorter course. It was 
reported that patients with mild to severe CAP, 
750 mg of levofloxacin per day for 5 days was as 





Based on Gyssens method, infection-related 
main illnesses, infection-related accompanying 
illnesses and doctors contribute significantly to 
the rationality or appropriateness of empiric 
antimicrobial use with a p-value of <0.01. 
Infection-related main illnesses, infection-related 
accompanying illnesses, doctors, age, and 
insurance did not contribute to the rationality of 
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